Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder

Schwann Shariatirad 1 , 2 , Alireza Mahjoub 1 , Ashraf Haqiqi 1 , Mohsen Rezaei Hemami 3 , Babak Tofighi 4 , Hamed Ekhtiari 5 , 6 and Mohammad Effatpanah 1 , *
Authors Information
1 Students Research Center of International Campus, Tehran University of Medical Sciences, Tehran, Iran
2 Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
3 Institute of Health & Wellbeing, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
4 Department of Population Health, New York University School of Medicine, New York, USA
5 Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
6 Iranian Institute for Cognitive Sciences Studies, Tehran, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: June 2018, 12 (2); e11529
  • Published Online: May 22, 2018
  • Article Type: Original Article
  • Received: March 5, 2017
  • Revised: June 21, 2018
  • Accepted: October 1, 2017
  • DOI: 10.5812/ijpbs.11529

To Cite: Shariatirad S, Mahjoub A, Haqiqi A, Rezaei Hemami M, Tofighi B, et al. Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder, Iran J Psychiatry Behav Sci. 2018 ;12(2):e11529. doi: 10.5812/ijpbs.11529.

Abstract
Copyright © 2018, Iranian Journal of Psychiatry and Behavioral Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. United Nations Office on Drugs and Crime. World Drug Report 2015. New York, USA: United Nations publication; 2015. 10 p.
  • 2. Radfar SR, Cousins SJ, Shariatirad S, Noroozi A, Rawson RA. Methamphetamine Use Among Patients Undergoing Methadone Maintenance Treatment in Iran; a Threat for Harm Reduction and Treatment Strategies: A Qualitative Study. Int J High Risk Behav Addiction. 2016;5(4). doi: 10.5812/ijhrba.30327.
  • 3. Shariatirad S, Maarefvand M, Ekhtiari H. Methamphetamine use and methadone maintenance treatment: an emerging problem in the drug addiction treatment network in Iran. Int J Drug Policy. 2013;24(6):e115-6. doi: 10.1016/j.drugpo.2013.05.003. [PubMed: 23773684].
  • 4. Alam-Mehrjerdi Z, Abdollahi M. The Persian methamphetamine use in methadone treatment in Iran: implication for prevention and treatment in an upper-middle income country. Daru. 2015;23:51. doi: 10.1186/s40199-015-0134-5. [PubMed: 26578071]. [PubMed Central: PMC4650324].
  • 5. Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian J Psychiatr. 2015;16:17-25. doi: 10.1016/j.ajp.2015.05.036. [PubMed: 26123235].
  • 6. Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 2014;97(1):37-44. doi: 10.1016/j.lfs.2013.07.014. [PubMed: 23892199]. [PubMed Central: PMC3870191].
  • 7. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry. 2005;13(3):141-54. doi: 10.1080/10673220591003605. [PubMed: 16020027].
  • 8. Brensilver M, Heinzerling KG, Swanson AN, Shoptaw SJ. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend. 2012;125(1-2):169-72. doi: 10.1016/j.drugalcdep.2012.03.027. [PubMed: 22534658]. [PubMed Central: PMC3418457].
  • 9. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442-8. doi: 10.1176/appi.ajp.2008.08020304. [PubMed: 18765480].
  • 10. Pereira FC, Gough B, Macedo TR, Ribeiro CF, Ali SF, Binienda ZK. Buprenorphine modulates methamphetamine-induced dopamine dynamics in the rat caudate nucleus. Neurotox Res. 2011;19(1):94-101. doi: 10.1007/s12640-009-9143-9. [PubMed: 20033362].
  • 11. Mori T, Ito S, Kita T, Narita M, Suzuki T, Sawaguchi T. Effects of mu-, delta- and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice. Eur J Pharmacol. 2006;532(1-2):81-7. doi: 10.1016/j.ejphar.2005.12.035. [PubMed: 16464448].
  • 12. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992;260(3):1185-93. [PubMed: 1545386].
  • 13. Salehi M, Emadossadat A, Kheirabadi GR, Maracy MR, Sharbafchi MR. The Effect of Buprenorphine on Methamphetamine Cravings. J Clin Psychopharmacol. 2015;35(6):724-7. doi: 10.1097/JCP.0000000000000408. [PubMed: 26468683].
  • 14. Nejati V. [Cognitive Abilities Questionnaire: Development and Evaluation of Psychometric Properties]. Adv Cognit Sci. 2013;15(2):11-9. Persian.
  • 15. Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89(5):563-72. [PubMed: 8044122].
  • 16. Hassani-Abharian P, Mokri A, Ganjgahi H, Oghabian MA, Ekhtiari H. Validation for Persian Versions of "Desire for Drug Questionnaire" and "Obsessive Compulsive Drug Use Scale" in Heroin Dependents. Arch Iran Med. 2016;19(9):659-65. [PubMed: 27631182].
  • 17. Cacciola JS, Alterman AI, McLellan AT, Lin YT, Lynch KG. Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend. 2007;87(2-3):297-302. doi: 10.1016/j.drugalcdep.2006.09.002. [PubMed: 17045423].
  • 18. Karimlou M, Salehi M, Zayeri F, Massah Choolabi O, Hatami A, Moosavy Khatat M. [Developing the Persian Version of the World Health Organization Quality of Life-100 Questionnaire]. Journal of Rehabilitation. 2011;4(11):73-82. Persian.
  • 19. Baker A, Lee NK, Claire M, Lewin TJ, Grant T, Pohlman S, et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction. 2005;100(3):367-78. doi: 10.1111/j.1360-0443.2005.01002.x. [PubMed: 15733250].
  • 20. Eastwood EC, Phillips TJ. Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake. Genes Brain Behav. 2014;13(2):226-35. doi: 10.1111/gbb.12100. [PubMed: 24152140]. [PubMed Central: PMC3976242].
  • 21. Eastwood EC, Phillips TJ. Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine. Addict Biol. 2014;19(3):370-9. doi: 10.1111/adb.12003. [PubMed: 23145527]. [PubMed Central: PMC3796126].
  • 22. Xu K, Seo D, Hodgkinson C, Hu Y, Goldman D, Sinha R. A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. Transl Psychiatry. 2013;3. e292. doi: 10.1038/tp.2013.62. [PubMed: 23962922]. [PubMed Central: PMC3756290].
  • 23. Sakoori K, Murphy NP. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl). 2004;172(2):129-36. doi: 10.1007/s00213-003-1643-3. [PubMed: 14624329].
  • 24. Feelemyer JP, Jarlais DCD, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251-8. doi: 10.1016/j.drugalcdep.2013.10.011. [PubMed: 24200104]. [PubMed Central: PMC3880839].
  • 25. Casares-Lopez MJ, Gonzalez-Menendez A, Festinger DS, Fernandez-Garcia P, Fernandez-Hermida JR, Secades R, et al. Predictors of retention in a drug-free unit/substance abuse treatment in prison. Int J Law Psychiatry. 2013;36(3-4):264-72. doi: 10.1016/j.ijlp.2013.04.003. [PubMed: 23706657].
  • 26. Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend. 2006;83(2):163-8. doi: 10.1016/j.drugalcdep.2005.11.008. [PubMed: 16343811].
  • 27. Rapeli P, Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol. 2011;11:13. doi: 10.1186/1472-6904-11-13. [PubMed: 21854644]. [PubMed Central: PMC3176473].
  • 28. Wee S, Vendruscolo LF, Misra KK, Schlosburg JE, Koob GF. A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Sci Transl Med. 2012;4(146):146ra110. doi: 10.1126/scitranslmed.3003948. [PubMed: 22875830]. [PubMed Central: PMC3448552].
  • 29. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002;97(10):1241-9. [PubMed: 12359026].
  • 30. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23(4):351-60. [PubMed: 12495797].
  • 31. Hollister LE, Johnson K, Boukhabza D, Gillespie HK. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 1981;8(1):37-41. [PubMed: 7297411].
  • 32. Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci. 2006;31(1):38-45. [PubMed: 16496034]. [PubMed Central: PMC1325065].
  • 33. Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Addiction. 2016;111(5):874-82. doi: 10.1111/add.13259. [PubMed: 26639678].
  • 34. Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D. Buprenorphine for cocaine and opiate dependence. Psychopharmacol Bull. 1992;28(1):15-9. [PubMed: 1609037].
  • 35. Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016;111(8):1416-27. doi: 10.1111/add.13375. [PubMed: 26948856]. [PubMed Central: PMC4940267].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments